India, Dec. 23 -- Aurobindo Pharma on Tuesday said it will acquire an additional 20 per cent stake in its China-based joint venture for USD 5.12 million.
The acquisition will be carried out by Helix Healthcare BV, a wholly owned subsidiary of Aurobindo Pharma, which has entered into a binding agreement with Shandong Luoxin Pharmaceutical Group Stock Co, the joint venture partner in Luoxin Aurovitas Pharma, the company said in a regulatory filing.
Luoxin Aurovitas Pharma is currently a 30:70 joint venture between Helix Healthcare BV and Shandong Luoxin.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....